Loading...
H. Lundbeck A/S
HLUBF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$3.70
$0.00(0.00%)
H. Lundbeck A/S (HLUBF) Financial Performance & Income Statement Overview
Review H. Lundbeck A/S’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
10.51%
↑ 10.51%
Operating Income Growth
2.35%
↑ 2.35%
Net Income Growth
37.25%
↑ 37.25%
Operating Cash Flow Growth
-18.48%
↓ 18.48%
Operating Margin
16.08%
↑ 16.08%
Gross Margin
81.04%
↑ 81.04%
Net Profit Margin
14.33%
↑ 14.33%
ROE
13.61%
↑ 13.61%
ROIC
7.91%
↑ 7.91%
H. Lundbeck A/S (HLUBF) Income Statement & Financial Overview
Review H. Lundbeck A/S's (HLUBF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $5.54B | $5.72B | $5.48B | $5.29B |
| Cost of Revenue | $1.07B | $1.09B | $1.10B | $1.06B |
| Gross Profit | $4.47B | $4.63B | $4.38B | $4.23B |
| Gross Profit Ratio | $0.81 | $0.81 | $0.80 | $0.80 |
| R&D Expenses | $1.12B | $1.52B | $889.00M | $933.00M |
| SG&A Expenses | $2.76B | $2.29B | $2.46B | $2.02B |
| Operating Expenses | $4.29B | $3.82B | $3.35B | $2.95B |
| Total Costs & Expenses | $5.36B | $4.91B | $4.45B | $4.01B |
| Interest Income | $0.00 | $0.00 | $0.00 | $29.00M |
| Interest Expense | $0.00 | $0.00 | $4.00M | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $467.00M | $468.00M |
| EBITDA | $739.00M | $811.00M | $1.004B | $1.76B |
| EBITDA Ratio | $0.13 | $0.14 | $0.18 | $0.33 |
| Operating Income | $177.00M | $811.00M | $1.03B | $1.28B |
| Operating Income Ratio | $0.03 | $0.14 | $0.19 | $0.24 |
| Other Income/Expenses (Net) | $503.00M | -$79.00M | -$30.00M | $29.00M |
| Income Before Tax | $680.00M | $732.00M | $1.00B | $1.31B |
| Income Before Tax Ratio | $0.12 | $0.13 | $0.18 | $0.25 |
| Income Tax Expense | $90.00M | -$45.00M | $230.00M | $301.00M |
| Net Income | $590.00M | $777.00M | $770.00M | $1.006B |
| Net Income Ratio | $0.11 | $0.14 | $0.14 | $0.19 |
| EPS | $0.59 | $0.78 | $0.78 | $1.01 |
| Diluted EPS | $0.59 | $0.78 | $0.78 | $1.01 |
| Weighted Avg Shares Outstanding | $991.23M | $996.15M | $987.18M | $992.01M |
| Weighted Avg Shares Outstanding (Diluted) | $991.23M | $996.15M | $987.18M | $992.01M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan